Literature DB >> 22811826

FDG PET imaging in the staging and management of gastric cancer.

Shane Hopkins1, Gary Y Yang.   

Abstract

Gastric cancer is a leading cause of cancer death worldwide. Complete resection offers the only chance for permanent control, and accurate staging and evaluation of treatment response are crucial for appropriate management. Positron Emission Tomography (PET) is increasingly used to complement anatomic imaging in cancer management. PET use in gastric cancer has been limited by 1) some gastric histologies are not PET avid, 2) spatial resolution limits the ability to distinguish between primary tumor and compartment I or II lymph nodes, and 3) the lack of a unified criteria in how to interpret PET for management decisions. New criteria have been proposed establishing response metrics in the utilization of PET. More study is needed to support these criteria in routine practice and establish the place of PET in the staging and management of gastric cancer.

Entities:  

Keywords:  gastric cancer; positron emission tomography; tumor staging

Year:  2011        PMID: 22811826      PMCID: PMC3397592          DOI: 10.3978/j.issn.2078-6891.2010.004

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  22 in total

1.  Accomplishments in 2008 in the management of esophageal cancer.

Authors:  Gary Y Yang; Katja Ott
Journal:  Gastrointest Cancer Res       Date:  2009-09

2.  Positron Emission Tomography's Utility in Esophageal Cancer Management.

Authors:  Shane Hopkins; Gary Y Yang
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

3.  Hydro-dynamic CT preoperative staging of gastric cancer: correlation with pathological findings. A prospective study of 107 cases.

Authors:  F D'Elia; A Zingarelli; D Palli; M Grani
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

Review 4.  Gastric cancer. Radiologic staging.

Authors:  F H Miller; M L Kochman; M S Talamonti; G G Ghahremani; R M Gore
Journal:  Radiol Clin North Am       Date:  1997-03       Impact factor: 2.303

Review 5.  Gastric cancer. Clinical and pathologic features.

Authors:  R M Gore
Journal:  Radiol Clin North Am       Date:  1997-03       Impact factor: 2.303

6.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.

Authors:  Karen Kinkel; Ying Lu; Marcus Both; Robert S Warren; Ruedi F Thoeni
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

Review 7.  Staging and preoperative evaluation of upper gastrointestinal malignancies.

Authors:  Eddie K Abdalla; Peter W T Pisters
Journal:  Semin Oncol       Date:  2004-08       Impact factor: 4.929

8.  Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT.

Authors:  J F Botet; C J Lightdale; A G Zauber; H Gerdes; S J Winawer; C Urmacher; M F Brennan
Journal:  Radiology       Date:  1991-11       Impact factor: 11.105

9.  Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer.

Authors:  T Fukuya; H Honda; T Hayashi; K Kaneko; Y Tateshi; T Ro; Y Maehara; M Tanaka; M Tsuneyoshi; K Masuda
Journal:  Radiology       Date:  1995-12       Impact factor: 11.105

Review 10.  Imaging of esophageal and gastric cancer.

Authors:  Wolfgang A Weber; Katja Ott
Journal:  Semin Oncol       Date:  2004-08       Impact factor: 4.929

View more
  16 in total

1.  Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer.

Authors:  Yuanhong Xu; Zhe Liu; Kejian Guo
Journal:  Mol Cell Biochem       Date:  2011-12-06       Impact factor: 3.396

Review 2.  New approaches to gastric cancer staging: beyond endoscopic ultrasound, computed tomography and positron emission tomography.

Authors:  Hyuk Yoon; Dong Ho Lee
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  The utility of positron emission tomography/computed tomography in target delineation for stereotactic body radiotherapy for liver metastasis from primary gastric cancer: an illustrative case report and literature review.

Authors:  Gary D Lewis; Stephen B Chiang; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2017-06

4.  Overexpression of ZEB1 associated with metastasis and invasion in patients with gastric carcinoma.

Authors:  Baoqing Jia; Hongyi Liu; Qinglong Kong; Bing Li
Journal:  Mol Cell Biochem       Date:  2012-03-31       Impact factor: 3.396

5.  Rab40b upregulation correlates with the prognosis of gastric cancer by promoting migration, invasion, and metastasis.

Authors:  Yuanyuan Li; Qingzhu Jia; Yu Wang; Fei Li; Zhengcai Jia; Ying Wan
Journal:  Med Oncol       Date:  2015-03-20       Impact factor: 3.064

6.  Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer.

Authors:  Kinga Grabinska; Maciej Pelak; Jerzy Wydmanski; Andrzej Tukiendorf; Andrea d'Amico
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 7.  Noninvasive detection of gastric cancer.

Authors:  Qin-Si Wan; Kun-He Zhang
Journal:  Tumour Biol       Date:  2016-07-06

8.  Expression of Rab25 correlates with the invasion and metastasis of gastric cancer.

Authors:  Chuanwu Cao; Chenhui Lu; Jichong Xu; Jiaxing Zhang; Jun Zhang; Maoquan Li
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

9.  Radiolabeling and evaluation of (64)Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer.

Authors:  Hua Zhu; Chuanke Zhao; Fei Liu; Lixin Wang; Junnan Feng; Zheng Zhou; Like Qu; Chengchao Shou; Zhi Yang
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

10.  Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells.

Authors:  Weiguo Cao; Rong Fan; Lifu Wang; Shidan Cheng; Hao Li; Jinsong Jiang; Mei Geng; Yening Jin; Yunlin Wu
Journal:  Tumour Biol       Date:  2012-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.